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The Role of Chest Imaging in Patient
Management During the COVID-19
Pandemic
A Multinational Consensus Statement From the Fleischner Society
Geoffrey D. Rubin, MD, MBA; Christopher J. Ryerson, MD, MAS; Linda B. Haramati, MD; Nicola Sverzellati, MD, PhD;
Jeffrey P. Kanne, MD; Suhail Raoof, MD; Neil W. Schluger, MD; Annalisa Volpi, MD; Jae-Joon Yim, MD;
Ian B. K. Martin, MD, MBA; Deverick J. Anderson, MD, MPH; Christina Kong, MD; Talissa Altes, MD; Andrew Bush, MD;
Sujal R. Desai, MD; Jonathan Goldin, MD, PhD; Jin Mo Goo, MD, PhD; Marc Humbert, MD, PhD;
Yoshikazu Inoue, MD, PhD; Hans-Ulrich Kauczor, MD; Fengming Luo, MD; Peter J. Mazzone, MD, MPH;
Mathias Prokop, MD, PhD; Martine Remy-Jardin, MD, PhD; Luca Richeldi, MD, PhD; Cornelia M. Schaefer-Prokop, MD;
Noriyuki Tomiyama, MD, PhD; Athol U. Wells, MD, PhD; and Ann N. Leung, MD

With more than 900,000 conﬁrmed cases worldwide and nearly 50,000 deaths during the ﬁrst
3 months of 2020, the coronavirus disease 2019 (COVID-19) pandemic has emerged as an
unprecedented health care crisis. The spread of COVID-19 has been heterogeneous, resulting in
some regions having sporadic transmission and relatively few hospitalized patients with COVID19 and others having community transmission that has led to overwhelming numbers of severe
cases. For these regions, health care delivery has been disrupted and compromised by critical
resource constraints in diagnostic testing, hospital beds, ventilators, and health care workers
who have fallen ill to the virus exacerbated by shortages of personal protective equipment.
Although mild cases mimic common upper respiratory viral infections, respiratory dysfunction
becomes the principal source of morbidity and mortality as the disease advances. Thoracic
imaging with chest radiography and CT are key tools for pulmonary disease diagnosis and
management, but their role in the management of COVID-19 has not been considered within
the multivariable context of the severity of respiratory disease, pretest probability, risk factors
for disease progression, and critical resource constraints. To address this deﬁcit, a multidisciplinary panel comprised principally of radiologists and pulmonologists from 10 countries with
experience managing patients with COVID-19 across a spectrum of health care environments
evaluated the utility of imaging within three scenarios representing varying risk factors, community conditions, and resource constraints. Fourteen key questions, corresponding to 11
decision points within the three scenarios and three additional clinical situations, were rated by
the panel based on the anticipated value of the information that thoracic imaging would be
expected to provide. The results were aggregated, resulting in ﬁve main and three additional
recommendations intended to guide medical practitioners in the use of chest radiography and
CT in the management of COVID-19.

ABBREVIATIONS: COVID-19 = coronavirus disease 2019; PPE = personal protection equipment; RT-PCR = reverse-transcriptase polymerase chain reaction; SARS-CoV2 = severe acute respiratory
syndrome coronavirus 2
AFFILIATIONS: From the Department of Radiology (Dr Rubin), Duke
University School of Medicine, Durham, NC; the Department of
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Medicine (Dr Ryerson), University of British Columbia, Vancouver,
BC, Canada; the Department of Radiology (Dr Haramati), Monteﬁore
Medical Center, Albert Einstein College of Medicine, Bronx, NY; the
Department of Scienze Radiologiche (Dr Sverzellati), Department of
Medicine and Surgery, University of Parma, Parma, Italy; the
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Summary
Structured around three scenarios and three key
situations, this Fleischner statement provides context for
the use of imaging to direct patient management during
the coronavirus disease 2019 pandemic in different
practice settings, different phases of epidemic outbreak,
and environments of varying critical resource
availability.

Department of Radiology (Dr Kanne), University of Wisconsin School
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Essentials
 Imaging is not indicated in patients suspected of
having coronavirus disease 2019 (COVID-19) and
mild clinical features unless they are at risk for
disease progression.
 Imaging is indicated in a patient with COVID-19
and worsening respiratory status.
 In a resource-constrained environment, imaging is
indicated for medical triage of patients suspected
of having COVID-19 who present with moderateto-severe clinical features and a high pretest
probability of disease.

On March 11, 2020, the World Health Organization
(WHO) ofﬁcially characterized the rapid global spread
of coronavirus disease 2019 (COVID-19) as a pandemic
and called for urgent international action in four key
areas: to prepare and be ready; to detect, protect, and
treat; to reduce transmission; and to innovate and learn.1
At the time of writing (April 1, 2020), there are more
than 900,000 conﬁrmed COVID-19 cases and nearly
50,000 deaths in 205 countries around the world, with
the majority of cases concentrated in four countries:
United States, Italy, Spain, and China.2,3 With sustained
community transmission now established in multiple
countries on multiple continents, the WHO public
health goal has changed from containment to mitigation
of the pandemic’s impact. Consequently, strategies are
now focused on efforts to reduce the incidence,
morbidity, and mortality of COVID-19 by breaking the
chain of human transmission through social distancing
and imposed quarantine.

Diagnostic Testing
Early detection and containment of infection caused by
the novel coronavirus severe acute respiratory syndrome
coronavirus 2 (SARS-CoV2) has been hindered by the
need to develop, mass produce, and widely disseminate
the required molecular diagnostic test, a real-time
reverse-transcriptase polymerase chain reaction (RTPCR) assay. Early reports of test performance in the
Wuhan, China, outbreak showed variable sensitivities
ranging from 37% to 71%.4,5 While laboratory-based
performance evaluations of RT-PCR tests show high
analytical sensitivity and near-perfect speciﬁcity with no
misidentiﬁcation of other coronaviruses or common
respiratory pathogens, test sensitivity in clinical practice
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may be adversely affected by a number of variables,
including adequacy of specimen, specimen type,
specimen handling, and stage of infection when the
specimen is acquired (Centers of Disease Control
guidelines for in-vitro diagnostics).6,7 False-negative RTPCR tests have been reported in patients with CT
ﬁndings of COVID-19 who eventually tested positive
with serial sampling.8 Limited testing capacity due to
insufﬁcient specimen collection kits, laboratory test
supplies, and testing equipment precluded early
widespread testing and is believed to have contributed to
rapid and unchecked transmission of infection within
communities by undetected individuals with milder,
limited, or no symptoms.9,10 For example, CT screening
of 82 asymptomatic individuals with conﬁrmed COVID19 from the cruise ship “Diamond Princess” showed
ﬁndings of pneumonia in 54%.11

Imaging Logistics During Pandemic
Provision of diagnostic imaging services to large
numbers of patients suspected of having or conﬁrmed to
have COVID-19 during an outbreak can be challenging,
as each study is lengthened and complicated by the need
for strict adherence to infection control protocols
designed to minimize risk of transmission and protect
health care personnel.12 Droplet transmission followed
by contaminated surfaces are believed to be the main
modes of spread for SARS-CoV2 in radiology suites; all
patients undergoing imaging should be masked and
imaged by using dedicated equipment that is cleaned
and disinfected after each patient encounter.13 Although

Materials and Methods

personal protection equipment (PPE) recommendations
vary between countries, the current Centers of Disease
Control and Prevention guidelines recommend
radiology staff wear a mask, goggles or face shield,
gloves, and an isolation gown. In countries with more
stringent PPE protocols, a surgical cap and shoe covers
may be added, while a surgical mask and goggles or face
shield are suggested in some countries with less stringent
PPE protocols.14 Additional precautions are required for
speciﬁc situations that are more likely to generate
aerosols, including patients receiving noninvasive
ventilation, during intubation or extubation, throughout
bronchoscopy, or when patients are receiving nebulized
therapies. Portable imaging, including imaging patients
through glass walls, has been used in some hospitals to
further reduce the chance of spreading infection.
Written from multidisciplinary and multinational
perspectives, this Fleischner statement is intended to
provide context for the use of imaging to direct patient
management during the COVID-19 pandemic in
different practice settings, different phases of epidemic
outbreak, and environments of varying critical resource
availability. This document is structured around three
clinical scenarios and three additional situations in
which chest imaging is often considered in the
evaluation of patients with potential COVID-19
infection. The committee elected to present this
document as a consensus statement rather than a
guideline given the limited evidence base and the urgent
need for direction on this topic for the medical
community.

This consensus statement is based on expert opinion among a panel of
15 thoracic radiologists, 10 pulmonologists and/or intensivists
(including one anesthesiologist), and one pathologist, as well as
additional experts in emergency medicine, infection control, and
laboratory medicine. The panel included individuals from the United
States, Italy, China, Germany, France, the United Kingdom, the
Netherlands, South Korea, Canada, and Japan, representing nine of
the 15 countries with the highest number of conﬁrmed COVID-19
cases reported worldwide as of April 1, 2020.2 The panel possessed
experience managing patients during periods of local viral
ampliﬁcation and critical resource constraints in Wuhan, China,
Northern Italy, and New York City.

clinically actionable information (Figs 1-3), with three additional
situations identiﬁed in which chest imaging is also often considered
(Fig 4). The entire panel was convened during a single session by
using a live audio and video interface (Zoom Video
Communications). The three scenarios and three additional
situations were presented, discussed, and reﬁned. The panel
independently and anonymously rated the appropriateness of
imaging with chest radiography or CT at each of these decision
points on a ﬁve-point scale. At least 70% agreement on the direction
of a recommendation was considered consensus. The scenarios are
intended to support the management of adults only. Children, who
are typically spared from severe infections,15 merit separate
consideration—particularly with regard to use of radiation-associated
procedures—and are beyond the scope of the current document.

A subcommittee composed of ﬁve radiologists, four pulmonologists
and/or intensivists (including one anesthesiologist), and one
emergency medicine physician identiﬁed and iteratively developed
three scenarios that illustrate imaging-related dilemmas occurring in
common clinical presentations and across varying risk factors,
community conditions, and resource constraints. These scenarios
included 11 distinct nodes where imaging potentially provides

The ﬁnal document was supported by a comprehensive literature search
for relevant articles. Using the search terms “((coronavirus OR COVID
OR SARS-CoV OR *nCoV*) AND (CT OR Computed Tomography OR
Radio* OR Imag*)),” a total of 137 English articles published between
December 1, 2019, and March 23, 2020, were identiﬁed. Each article
was assessed for relevance to the primary objective, and a summary of
key ﬁndings from relevant articles was created.
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Figure 1 – Diagram illustrates the ﬁrst of three clinical scenarios presented to the panel with ﬁnal recommendations. Mild features refer to absence of
signiﬁcant pulmonary dysfunction or damage. Pretest probability is based on background prevalence of disease and may be further modiﬁed by individual’s exposure risk. The absence of resource constraints corresponds to sufﬁcient availability of personnel, personal protective equipment, coronavirus disease 2019 (COVID-19) testing, hospital beds, and/or ventilators with the need to rapidly triage patients. Numbers in blue circles indicate key
questions referenced in the text and presented in Figure 4. Contextual detail and considerations for imaging with chest radiography versus CT are
presented in the text. Although not covered by this scenario and not shown in the ﬁgure, in the presence of substantial resources constraints, there is no
role for imaging of patients with mild features of COVID-19. * ¼ Clinical judgment should dictate the use of imaging through consideration of patient
risk factors and local resources. Mod ¼ moderate; Neg ¼ negative; Pos ¼ positive.

Figure 2 – Diagram illustrates the second of three clinical scenarios presented to the panel with ﬁnal recommendations. Moderate-to-severe features
refer to evidence of signiﬁcant pulmonary dysfunction or damage. Pretest probability is based on background prevalence of disease and may be further
modiﬁed by individual’s exposure risk. The absence of resource constraints corresponds to sufﬁcient availability of personnel, personal protective
equipment, coronavirus disease 2019 (COVID-19) testing, hospital beds, and/or ventilators with the need to rapidly triage patients. Numbers in blue
circles indicate key questions referenced in the text and presented in Figure 4. Contextual detail and considerations for imaging with chest radiography
versus CT are presented in the text. Alt Dx ¼ alternate diagnosis; Neg ¼ negative; Pos ¼ positive.

chestjournal.org
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Figure 3 – Diagram illustrates the third of three clinical scenarios presented to the panel with ﬁnal recommendations. Moderate-to-severe features refer
to evidence of signiﬁcant pulmonary dysfunction or damage. High pretest probability is based on high background prevalence of disease associated with
community transmission. Rapid coronavirus disease 2019 (COVID-19) test is a point-of-care test with a turnaround time of less than 1 hour. Numbers
in blue circles indicate key questions referenced in the text and presented in Figure 4. Contextual detail and considerations for imaging with chest
radiography (CXR) versus CT are presented in the text. * ¼ Lower priority if severely resource constrained, relative to question 10 or 11. Alt Dx ¼
alternate diagnosis; Neg ¼ negative; Pos ¼ positive; PPE ¼ personal protection equipment.

Use of Imaging in COVID-19
The value of an imaging test relates to the generation of
results that are clinically actionable either for
establishing a diagnosis or for guiding management,
triage, or therapy. That value is diminished by costs that
include the risk of radiation exposure to the patient, risk
of COVID-19 transmission to uninfected health care
workers and other patients, consumption of PPE, and
need for cleaning and downtime of radiology rooms in
resource-constrained environments. The appropriate use
of imaging in each of the scenarios was considered on
this basis.
This statement focuses exclusively on the use of chest
radiography and CT of the thorax. Although US has
been suggested as a potential triage and diagnostic tool
for COVID-19 given the predilection for the disease in
subpleural regions, there is limited experience at this
time16 as well as infection control issues.
Chest radiography is insensitive in mild or early
COVID-19 infection.17 However, with respect to the
relative value of chest radiography or CT for detecting
the presence of viral pneumonia, the experience is vastly
different depending on community norms and public
health directives. When patients are encouraged to
present early in the course of their disease, as was the

110 Guidelines and Consensus Statements

case in Wuhan, China, chest radiography has little value.
The greater sensitivity of CT for early pneumonic
changes is more relevant in the setting of a public health
approach that required isolation of all infected
patients within an environment where the reliability of
COVID-19 testing was limited and turnaround times
were long.4 Alternatively, in New York City, where
patients were instructed to stay at home until they
experienced advanced symptoms, chest radiographs
were often abnormal at the time of presentation.
Equipment portability with imaging performed within
an infected patient’s isolation room is another factor that
may favor chest radiography in selected populations,
effectively eliminating the risk of COVID-19
transmission along the transport route to a CT scanner
and within the room housing a CT scanner, particularly
in environments lacking PPE. In hospitalized patients,
chest radiography can be useful for assessing disease
progression and alternative diagnoses (eg, lobar
pneumonia suggestive of bacterial superinfection,
pneumothorax, and pleural effusion).
CT is more sensitive for early parenchymal lung disease,
disease progression, and alternative diagnoses including
acute heart failure from COVID-19 myocardial injury18
and, when performed with intravenous contrast
material, pulmonary thromboembolism. Leveraging
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Figure 4 – Panel members (n ¼ 27) developed 14 key questions used to support creation of common scenarios and recommendations related to the use
of chest imaging in patients with features of coronavirus disease 2019 (COVID-19). The proportion of panel member votes for each question is presented
on a 5-point scale as well as a summary column that shows the total percentage of committee members who voted for or against imaging for each key
question, excluding those members who were neutral or who abstained (one panel member abstained for questions 1 and 2). Numbers in left column
correspond to question numbers in text and Figures 1-3. PoC ¼ point of care.

these superior capabilities depends on the availability of
CT capacity, particularly considering the potential
reduction in CT scanner availability due to the
additional time required to clean and disinfect
equipment after imaging of patients suspected of having
COVID-19. Some centers rely on the improved
depiction of COVID-19 ﬁndings with CT relative to
chest radiography19 and their association with clinical
worsening to determine patient disposition to home,
hospital admission, or intensive care. In recognition of
variance among local practice patterns and resource
availability, it is important to state at the outset that the
scenarios specify the use of imaging but do not articulate
the relative merit of chest radiography versus CT.
Ultimately, the choice of imaging modality is left to the
judgment of clinical teams at the point of care,

chestjournal.org

accounting for the differing attributes of chest
radiography and CT, local resources, and expertise.

Overview of Clinical Scenarios
The scenarios apply only to patients presenting with
features consistent with COVID-19 infection. The
severity of respiratory disease and pretest probability of
COVID-19 infection are speciﬁed for each scenario, with
additional key considerations including the presence of
risk factors for disease progression, evidence of disease
progression, and the presence of substantial critical
resource constraints (Table 1). The scenarios help
distinguish mild respiratory disease from moderate-tosevere respiratory disease on the basis of the absence
versus presence of signiﬁcant pulmonary dysfunction or
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damage. Pretest probability is deﬁned by the background
prevalence of infection and can be estimated with
observed transmission patterns, as follows: low with
sporadic transmission, moderate with clustered
transmission, and high with community transmission.20
Individual pretest probability is further modiﬁed if there
is known exposure through contact with a person
conﬁrmed to have COVID-19.21 For health care
providers, the Centers for Disease Control and
Prevention22 categorizes medical-related exposures into
low-, medium-, and high-risk groups. Within a
diagnostic radiology department, brief (a few minutes or
less) unprotected interaction with a patient with
COVID-19 and prolonged close contact with a masked,
infected patient by a medical provider wearing PPE are
categorized as low-risk exposures.21,22 Risk factors for
poor outcomes in patients with COVID-19 infection are
considered separately from pretest probability, with
common risk factors including age older than 65 years,
cardiovascular disease, diabetes, chronic respiratory
disease, hypertension, and immune-compromised
status.23 Identifying a patient as being at high risk for
COVID-19 progression is not necessarily a feature of
any single risk factor but is rather a clinical judgment
based on the combination of underlying comorbidities
and general health status that suggests a higher level of
clinical concern. Where appropriate, management
variations based on risk factors for disease progression
are called out explicitly, as in scenario 1. All clinical
scenarios begin by characterizing COVID-19 status
based on the availability of laboratory test results.

Scenario 1: Mild Features of COVID-19
The ﬁrst scenario (Fig 1) addresses a patient presenting
for evaluation at an outpatient clinic or via telehealth
with mild respiratory features consistent with COVID19 infection, any pretest probability of COVID-19
infection, and no signiﬁcant critical resource constraints.
When COVID-19 test results are unavailable, patients
with moderate-to-high pretest probability should be
initially managed as if COVID-19 testing is positive,
whereas patients with low pretest probability should be
initially managed as if COVID-19 testing is negative.
Imaging is advised for patients with risk factors for
COVID-19 progression and either positive COVID-19
testing or moderate-to-high pretest probability in the
absence of COVID-19 testing (Fig 1, question 1).
Imaging provides a baseline for future comparison, may
establish manifestations of important comorbidities in
patients with risk factors for disease progression
(Table 1), and may inﬂuence the intensity of monitoring
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TABLE 1 ]

Deﬁnitions and Criteria for Key Components
of Common Clinical Scenarios

Severity of respiratory disease
Mild: no evidence of signiﬁcant pulmonary dysfunction
or damage (eg, absence of hypoxemia, no or mild
dyspnea)
Moderate to severe: evidence of signiﬁcant pulmonary
dysfunction or damage (eg, hypoxemia, moderateto-severe dyspnea)
Pretest probability
Based on background prevalence of disease as
estimated by observed transmission patterns. May
be further modiﬁed by individual’s exposure risk.
Subcategorized as:
Low: sporadic transmission
Medium: clustered transmission
High: community transmission
Risk factors for disease progression
Present: clinical judgment regarding combination of
age >65 years and presence of comorbidities (eg,
cardiovascular disease, diabetes, chronic
respiratory disease, hypertension, immunecompromised)
Absent: deﬁned by the absence of risk factors for
disease progression
Disease progression
Progression of mild disease to moderate-to-severe
disease as deﬁned above
Progression of moderate-to-severe disease with
worsening objective measures of hypoxemia
Resource constraints
Limited access to personnel, personal protective
equipment, COVID-19 testing ability (including
swabs, reagent, or personnel), hospital beds, and/
or ventilators with the need to rapidly triage
patients
COVID-19 ¼ coronavirus 2019.

for clinical worsening. Imaging is not advised for
patients with mild features who are COVID-19 positive
without accompanying risk factors for disease
progression or for patients with mild features who are
COVID-19 negative (Fig 1, questions 2 and 3). The
panel believed that the yield of imaging in these settings
would be very low and that it was safe for most patients
to self-monitor for clinical worsening. Regardless of
COVID-19 test results and risk factors, imaging is
advised for patients with mild clinical features who
subsequently develop clinical worsening (Fig 1,
questions 4 and 5). In the absence of clinical worsening,
management involves support and isolation of patients
with positive COVID-19 testing or patients with
moderate-to-high pretest probability without COVID19 test results available.
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Although not speciﬁcally addressed with this scenario, in
the presence of substantial resources constraints there is
no role for imaging of patients with mild features of
COVID-19.

Scenario 2: Moderate-to-Severe Features of
COVID-19
The second scenario (Fig 2) addresses a patient
presenting with moderate-to-severe features consistent
with COVID-19 infection, any pretest probability of
COVID-19 infection, and no substantial critical resource
constraints. Separate ratings were obtained for COVID19-positive patients and either COVID-19-negative
patients or patients for whom COVID-19 testing is
unavailable (Fig 2, questions 6 and 7). Imaging is
advised regardless of the results or availability of
COVID-19 testing given the impact of imaging in both
circumstances.
For COVID-19-positive patients, imaging establishes
baseline pulmonary status and helps identify underlying
cardiopulmonary abnormalities that may facilitate risk
stratiﬁcation for clinical worsening. In the presence of
clinical worsening, imaging is again advised to assess for
COVID-19 progression or secondary cardiopulmonary
abnormalities such as pulmonary embolism,
superimposed bacterial pneumonia, or heart failure that
can potentially be secondary to COVID-19 myocardial
injury (Fig 2, question 8).
For COVID-19-negative patients or any patient for
whom testing is not performed, imaging may reveal an
alternative diagnosis to explain the patient’s clinical
features. This should direct patient care as per existing
clinical guidelines or standard clinical practice. If an
alternative diagnosis is not revealed or images
demonstrate features of COVID-19 infection, then
subsequent clinical evaluation would depend on the
pretest probability of COVID-19 infection and COVID19 test availability. Falsely negative COVID-19 testing is
more prevalent in high pretest probability
circumstances, and repeat COVID-19 testing is therefore
advised if available. Depending on the imaging ﬁndings,
other clinical investigations may be pursued.

Scenario 3: Moderate-To-Severe Features of
COVID-19 in a Resource-constrained
Environment
The third scenario (Fig 3) addresses a patient presenting
with moderate-to-severe features consistent with
COVID-19 infection within an environment of high
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community disease burden and critical resource
limitations as seen in Wuhan, China, in regions of Italy
and Spain, and in New York City. Because health care
personnel and infrastructure may be overwhelmed by a
high inﬂux of new patients and resources are limited to
provide critical care, urgent decision-making and triage
are of primary importance. At the time of this writing,
turnaround times for COVID-19 test results range from
6 to over 48 hours, with most sites waiting at least 12
hours for results. This is an impractically long time
period to consider triage to limited hospital beds and
ventilators. However, rapid point-of-care COVID-19
tests are expected to be released into clinical
environments during the 1st week of April 2020,
providing routine turnaround times of less than an hour
and potentially as little as 5 minutes.24-27 Although the
initial availability and sample processing capacity of
point-of-care COVID-19 testing is expected to be
limited, this should increase over time.
The third scenario ﬁrst considers the potential
availability of point-of-care COVID-19 testing. Imaging
is advised when point-of-care COVID-19 testing is
available and results are positive (Fig 3, question 9) for
the same reasons as described for scenario 2. On the
basis of imaging ﬁndings and clinical features, patients
are subsequently supported and monitored with a level
of intensity consistent with clinical features. Imaging is
again indicated if patients subsequently clinically worsen
(Fig 3, question 11).
Imaging is advised to support more rapid triage of
patients in a resource-constrained setting when pointof-care COVID-19 testing is not available or results are
negative (Fig 3, question 10). Imaging may reveal
features of COVID-19, which within this scenario may
be taken as a presumptive diagnosis of COVID-19 for
medical triage and associated decisions regarding
disposition, infection control, and clinical management.
In this high pretest probability environment, and as
described for scenario 2, the possibility of falsely
negative COVID-19 testing creates a circumstance
where a COVID-19 diagnosis may be presumed when
imaging ﬁndings are strongly suggestive of COVID-19
despite negative COVID-19 testing. This guidance
represents a variance from other published
recommendations that advise against the use of imaging
for the initial diagnosis of COVID-1928 and was
supported by direct experience among panelists
providing care within the conditions described for this
scenario. The relationship between disease severity and
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triage may need to be ﬂuid depending on resources and
case load. When imaging reveals an alternative diagnosis
to COVID-19, management is based on established
guidelines or standard clinical practice.

TABLE 2 ]

Summary of Recommendations for Imaging

Main recommendations
Imaging is not routinely indicated as a screening test
for COVID-19 in asymptomatic individuals

Additional Key Questions

Imaging is not indicated for patients with mild features
of COVID-19 unless they are at risk for disease
progression (scenario 1)

Daily Chest Radiographs Are Not Indicated in
Stable Intubated Patients with COVID-19
(Question 12)

Imaging is indicated for patients with moderate to
severe features of COVID-19 regardless of
COVID-19 test results (scenarios 2 and 3)

Multiple studies have shown no difference in important
outcomes (mortality, length of stay, and ventilator days)
for patients in the intensive care unit imaged ondemand as compared with a daily routine protocol.29-32
Avoidance of non-value-added imaging is particularly
important in the COVID-19 patient population to
minimize exposure risk of radiology technologists and to
conserve PPE.

Imaging is indicated for patients with COVID-19 and
evidence of worsening respiratory status (scenarios
1, 2, and 3)

CT Is Indicated in a Patient with Functional
Impairment and/or Hypoxemia after Recovery
from COVID-19 (Question 13)

With the recent emergence of SARS-CoV2 as a human
pathogen, there are no long-term follow-up studies of
survivors. Postmortem evaluation of a patient who
succumbed to severe COVID-19 showed pathologic
ﬁndings consistent with diffuse alveolar damage, similar
to ﬁndings previously described with severe acute
respiratory syndrome and Middle East respiratory
syndrome.33 Patients with functional impairment after
recovery from COVID-19 should undergo imaging to
differentiate between expected morphologic
abnormalities as sequelae of infection, mechanical
ventilation, or both versus a different and potentially
treatable process.
COVID-19 Testing Is Indicated in a Patient Who Is
Found Incidentally to Have Typical Findings of
COVID-19 at CT (Question 14)

Although CT ﬁndings of COVID-19 infection are
nonspeciﬁc, their presence in an asymptomatic patient
with no or mild respiratory symptoms is concerning in a
setting of known community transmission, particularly
if there is no better alternative diagnosis. Asymptomatic
carriers of COVID-19 have been estimated to comprise
17.9%-33.3% of all infected cases.34,35 Asymptomatic
infection with CT ﬁndings suggestive of COVID-19 in
the lung has been documented in screened cruise ship
passengers.11 It is believed that the presence of
undetected infected and mildly symptomatic or
asymptomatic individuals may be contributing to the
rapid geographic spread of SARS-CoV2 (9). RT-PCR
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In a resource-constrained environment where access
to CT is limited, chest radiography may be preferred
for patients with COVID-19 unless features of
respiratory worsening warrant the use of CT
(scenarios 2 and 3)
Additional recommendations
Daily chest radiographs are NOT indicated in stable
intubated patients with COVID-19
CT is indicated in patients with functional impairment
and/or hypoxemia after recovery from COVID-19
COVID-19 testing is indicated in patients incidentally
found to have ﬁndings suggestive of COVID-19 on a
CT scan
See Table 1 legend for expansion of abbreviation.

testing in this scenario is important to potentially
identify an occult infection and limit further
transmission both within the community and in the
environment where the patient is receiving medical care.
In highly prevalent areas, an additional uncertainty is
whether CT should be used as a screening tool either as
a stand-alone or as an adjunct to RT-PCR to exclude
occult infection before surgery or intensive
immunosuppressive therapies.
The panel’s ratings are provided in Figure 4, and a
summary of all recommendations is provided in Table 2.

Additional Resources
For purposes of image interpretation and reporting,
readers are referred to a recently published systematic
review of imaging ﬁndings of COVID-1936 and a
multisociety consensus paper on reporting chest CT
ﬁndings related to COVID-19.37 As an aid to improving
radiologist and pulmonologist familiarity with the
imaging ﬁndings of COVID-19, an educational
repository of proven COVID-19 cases can be found at
the Fleischner Society website (https://www.ﬂeischnercovid19.org).
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Conclusion
This statement is intended to offer guidance to
physicians on the use of thoracic imaging across a
breadth of health care environments. It represents the
collective opinions and perspectives of thoracic
radiology, pulmonology, intensive care, emergency
medicine, laboratory medicine, and infection control
experts practicing in 10 countries, representative of the
highest burden of coronavirus disease 2019 (COVID-19)
worldwide. It also represents opinion at a moment in
time within a highly dynamic environment where the
status of regional epidemics and the availability of
critical resources to combat those epidemics vary daily.
The evidence base supporting the use of imaging across
the scenarios presented is scant and the advice presented
herein may undergo reﬁnement through rigorous
scientiﬁc investigation, exposing nuances of image
interpretation that may lead to prognostic information
and guide management decisions. At the time of this
writing, no therapy has been conﬁrmed to alter the
course of COVID-19, there is no known cure, and there
is no vaccine for prevention. As effective treatments are
developed, thoracic imaging may ﬁnd new roles by
establishing treatment response or characterizing
patients as likely responders to novel therapies.
Author contributions: G. D. R., M. H., C. M. S.-P., and A. N. L. are
guarantors of integrity of the entire study. All authors contributed to
study concepts/study design or data acquisition or data analysis/
interpretation, contributed to manuscript drafting or manuscript
revision for important intellectual content, approved the ﬁnal version
of the submitted manuscript, agree to ensure any questions related to
the work are appropriately resolved, and contributed to manuscript
editing. G. D. R., C. J. R., L. B. H., N. S., S. R., N. W. S., J.-J. Y., D. J. A.,
C. K., A. B., S. R. D., J. G., M. H., Y. I., H.-U. K., F. L., M. R.-J., C. M. S.P., and A. N. L. contributed to the literature research. J. P. K., N. W. S.,
A. V., A. B., H.-U. K., F. L., and N. T. contributed to the clinical studies.
I. B. K. M., Y. I., and A. N. L. contributed to the experimental studies.
G. D. R. contributed to the statistical analysis.
Financial/nonﬁnancial disclosures: The authors have reported to
CHEST the following: J. P. K. is a consultant for Parexel International,
outside the submitted work. D. J. A. received grants from AHRQ and
CDC and receives royalties from Up to Date, outside the submitted
work. T. A. received speakers fees from Philips and is a paid consultant
for Vertex, outside the submitted work. J. M. G. received research
grants from Inﬁnitt Healthcare and Dongkook Lifescience, outside the
submitted work. H.-U. K. received a grant and nonﬁnancial support
from Siemens; received a grant and personal fees from Philips; received
nonﬁnancial support from Bayer; and received fees for speakers bureau
from Boehringer Ingelheim, MSD, and Astra Zeneca, outside the
submitted work. M. P. received a grant and speakers fees from Siemens
Healthineers, received a grant and speakers fees from Canon Medical
Systems, and received speakers fees from Bracco and Bayer, outside the
submitted work. M. R.-J. received clinical research support from
Siemens Healthineers, outside the submitted work. L. R. is a paid
consultant for Biogen, ImmuneWorks, Celgen, and Nitto; received a
grant from Roche; received a grant from Boehringer Ingelheim; is paid
by Roche, Boehringer Ingelheim, and FibroGen to be a member of the
advisory board; and is paid to be on the steering committee at
Boehringer Ingelheim, outside the submitted work. C. M. S.-P. is a

chestjournal.org

member of the Dutch COVID Working Group, outside the submitted
work. None declared (G. D. R., C. J. R., L. B. H., N. S., S. R., N. W. S., A.
V., J.-J. Y., I. B. K. M., C. K., A. B., S. R. D., J. G., M. H., Y. I., F. L., P. J.
M., N. T., A. U. W., A. N. L.).

References
1. World Health Organization. Director-General’s opening remarks at
the media brieﬁng on COVID-19 - March 11, 2020. https://www.
who.int/dg/speeches/detail/who-director-general-s-openingremarks-at-the-media-brieﬁng-on-covid-19—11-march-2020.
Accessed April 1, 2020.
2. World Health Organization. Coronavirus disease (COVID-19)
situation dashboard. https://experience.arcgis.com/experience/685
d0ace521648f8a5beeeee1b9125cd. Accessed April 1, 2020.
3. Johns Hopkins University. Coronavirus COVID-19 global cases by
the Center for Systems Science and Engineering (CSSE). https://
gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda75
94740fd40299423467b48e9ecf6. Accessed April 1, 2020.
4. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR
testing in coronavirus disease 2019 (COVID-19) in China: a report
of 1014 cases [published online ahead of print February 26, 2020].
Radiology. https://doi.org/10.1148/radiol.2020200642.
5. Li Y, Yao L, Li J, et al. Stability issues of RT-PCR testing of SARSCoV-2 for hospitalized patients clinically diagnosed with COVID-19
[published online ahead of print March 26, 2020]. J Med Virol.
https://doi.org/10.1002/jmv.25786.
6. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in
different types of clinical specimens. JAMA. 2020;323(18):18431844.
7. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper
respiratory specimens of infected patients. N Engl J Med.
2020;382(12):1177-1179.
8. Fang Y, Zhang H, Xie J, et al. Sensitivity of chest CT for COVID-19:
comparison to RT-PCR [published online ahead of print February
19, 2020]. Radiology. https://doi.org/10.1148/radiol.2020200432.
9. Li R, Pei S, Chen B, et al. Substantial undocumented infection
facilitates the rapid dissemination of novel coronavirus (SARSCoV2). Science. In press.
10. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV
infection from an asymptomatic contact in Germany. N Engl J Med.
2020;382(10):970-971.
11. Inui S, Fujikawa A, Jitsu M, et al. Findings in cases from the cruise
ship “Diamond Princess” with coronavirus disease 2019 (COVID19). Radiol Cardiothorac Imaging. 2020;2(2):e200110.
12. Mossa-Basha M, Meltzer CC, Kim DC, Tuite MJ, Kolli KP, Tan BS.
Radiology department preparedness for COVID-19: Radiology
Scientiﬁc Expert Panel [published online ahead of print March 16,
2020]. Radiology. https://doi.org/10.1148/radiol.2020200988.
13. Kooraki S, Hosseiny M, Myers L, Gholamrezanezhad A. Coronavirus
(COVID-19) outbreak: what the department of radiology should
know. J Am Coll Radiol. 2020;17(4):447-451.
14. Centers for Disease Control and Prevention. Coronavirus disease
2019 (COVID-19) interim infection prevention and control
recommendations. https://www.cdc.gov/coronavirus/2019-ncov/
infection-control/control-recommendations.html#adhere. Accessed
April 1, 2020.
15. Dong Y, Mo X, Hu Y, et al. Epidemiological characteristics of 2143
pediatric patients with 2019 coronavirus disease in China. Pediatrics.
In press.
16. Soldati G, Smargiassi A, Inchingolo R, et al. Is there a role for lung
ultrasound during the COVID-19 pandemic [published online ahead
of print March 20, 2020]? J Ultrasound Med. https://doi.org/10.1002/
jum.15284.
17. Wong HYF, Lam HYS, Fong AH, et al. Frequency and distribution
of chest radiographic ﬁndings in COVID-19 positive patients
[published online ahead of print March 27, 2019]. Radiology. https://
doi.org/10.1148/radiol.2020201160.

115

18. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular
considerations for patients, health care workers, and health systems
during the coronavirus disease 2019 (COVID-19) pandemic. J Am
Coll Cardiol. 2020;75(18):2352-2371.
19. Orsi MA, Oliva AG, Cellina M. Radiology department preparedness
for COVID-19: facing an unexpected outbreak of the disease.
Radiology. 2020;295(3):E8.
20. World Health Organization. Critical preparedness, readiness and
response actions for COVID-19. https://www.who.int/emergencies/
diseases/novel-coronavirus-2019/technical-guidance/criticalpreparedness-readiness-and-response-actions-for-covid-19.
Accessed April 1, 2020.
21. Centers for Disease Control and Prevention. Coronavirus disease
2019 (COVID-19) public health recommendations for communityrelated exposure. https://www.cdc.gov/coronavirus/2019-ncov/php/
public-health-recommendations.html. Accessed April 1, 2020.
22. Centers for Disease Control and Prevention. Interim U.S. guidance
for risk assessment and public health management of healthcare
personnel with potential exposure in a healthcare setting to patients
with coronavirus disease (COVID-19). https://www.cdc.gov/
coronavirus/2019-ncov/hcp/guidance-risk-assesment-hcp.html.
Accessed April 1, 2020.
23. Wu Z, McGoogan JM. Characteristics of and important lessons from
the coronavirus disease 2019 (COVID-19) outbreak in China:
summary of a report of 72 314 cases from the Chinese Center for
Disease Control and Prevention [published online ahead of print
February 24, 2020]. JAMA. https://doi.org/10.1001/jama.2020.2648.
24. DiaSorin Molecular. Simplexa COVID-19 Direct Kit. https://
molecular.diasorin.com/us/kit/simplexa-covid-19-direct-kit/.
Accessed April 1, 2020.
25. bioMérieux. First of 3 diagnostic tests for SARS-CoV-2 coronavirus
available from bioMérieux. https://www.biomerieux.com/en/novelcoronavirus-covid-19. Accessed April 1, 2020.
26. Cepheid. Xpert Xpress SARS-CoV-2 has received FDA emergency
use authorization. https://www.cepheid.com/coronavirus. Accessed
April 1, 2020.
27. Abbott ID. NOW COVID-19 Molecular. In minutes. On the front
line. https://www.alere.com/en/home/product-details/id-nowcovid-19.html. Accessed April 1, 2020.

116 Guidelines and Consensus Statements

28. American College of Radiology. ACR recommendations for the use
of chest radiography and computed tomography (CT) for suspected
COVID-19 infection. https://www.acr.org/Advocacy-andEconomics/ACR-Position-Statements/Recommendations-for-ChestRadiography-and-CT-for-Suspected-COVID19-Infection. Accessed
April 1, 2020.
29. Oba Y, Zaza T. Abandoning daily routine chest radiography in the
intensive care unit: meta-analysis. Radiology. 2010;255(2):386-395.
30. Hejblum G, Chalumeau-Lemoine L, Ioos V, et al. Comparison of
routine and on-demand prescription of chest radiographs in
mechanically ventilated adults: a multicentre, cluster-randomised,
two-period crossover study. Lancet. 2009;374(9702):1687-1693.
31. Lakhal K, Serveaux-Delous M, Lefrant JY, Capdevila X, Jaber S.
AzuRéa network for the RadioDay study group. Chest radiographs
in 104 French ICUs: current prescription strategies and clinical
value (the RadioDay study). Intensive Care Med. 2012;38(11):17871799.
32. Suh RD, Genshaft SJ, Kirsch J, et al. ACR Appropriateness CriteriaÒ
intensive care unit patients. J Thorac Imaging. 2015;30(6):W63-W65.
33. Xu Z, Shi L, Wang Y, et al. Pathological ﬁndings of COVID-19
associated with acute respiratory distress syndrome. Lancet Respir
Med. 2020;8(4):420-422.
34. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the
asymptomatic proportion of coronavirus disease 2019 (COVID-19)
cases on board the Diamond Princess cruise ship, Yokohama, Japan,
2020. Euro Surveill. 2020;25(10).
35. Nishiura H, Kobayashi T, Suzuki A, et al. Estimation of the
asymptomatic ratio of novel coronavirus infections (COVID-19). Int
J Infect Dis. 2020;94:154-155.
36. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A.
Coronavirus disease 2019 (COVID-19): a systematic review of
imaging ﬁndings in 919 patients [published online ahead of print
March 14, 2020]. AJR Am J Roentgenol. https://doi.org/10.2214/
AJR.20.23034.
37. Simpson S, Kay FU, Abbara A, et al. Radiological Society of North
America expert consensus statement on reporting chest CT ﬁndings
related to COVID-19. Endorsed by the Society of Thoracic
Radiology, the American College of Radiology, and RSNA. Radiol
Cardiothorac Imaging. 2020;2(2):e200152.

[

158#1 CHEST JULY 2020

]

